Clinical Study on the Treatment of Herpes Zoster Pain With Dexmedetomidine Combined With Long-term High Voltage

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2

Total Enrollment

92 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-12-16

Study Completion Date

2026-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Participants will be invited to take part in clinical research. This informed consent form will provide information to the participants to help them decide whether to participate in the clinical study. If participants have any questions, please ask them directly to the researcher in charge of this study. This study was approved by the Biomedical Research Ethics Review Committee of the Institute. This trial is a randomized controlled clinical study. According to the different treatment methods, the control group was randomly divided into the control group and the experimental group. Control group: On the basis of conventional drug treatment, long-term high-voltage pulsed radiofrequency treatment was carried out. Experimental group: On the basis of conventional drug treatment, dexmedetomidine nasal spray was administered before HL-PRF treatment, before bedtime on the day of the operation, and before bedtime on the 1st to 3rd days after the operation. Heart rate, blood pressure and blood oxygen saturation were monitored respectively before the operation, during the operation and after the operation. Telephone follow-ups were conducted at 1 week, 1 month, 3 months and 6 months after the operation respectively. If the participants agree to participate in this study, the researchers will number the participants and establish medical records. The researchers will have detailed communication with the participants or their families, inform them of the research situation, and ask the participants to provide disease information, including the onset of the disease, family history, previous medical visits and some examination results.

What do you need to do in this research? Once participating in the study, participants will be required to provide true information about their medical history and current physical condition. Tell the research doctor about any discomfort you encountered during the research process; Do not take restricted drugs, foods, etc. Tell the research doctor whether you have participated in or are currently participating in any other research recently.

Risks and discomfort: Communicating and talking with researchers may cause participants to feel psychologically uncomfortable.

Since this study only collected the medical history, data and epidemiological investigation of patients or normal people, there is no harm in this study. If participants are injured during the clinical trial, they can receive free treatment and/or appropriate compensation in accordance with Chinese law.

What are the benefits of participating in this research? Useful information can be provided for disease research by studying the information of the participants.

The cost of participating in this study: Participation in this study will be based on the medical information of the research participants, and the related costs will not be borne by the participants.

Privacy issue: If participants decide to take part in this study, their participation status and personal data during the study period will be kept confidential. When necessary, government administrative departments or members of the ethics review committee may access the personal data of participants in research institutions. When the results of this study are announced, the personal identity information of the participants will not be disclosed.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

High-Voltage Long-Duration Pulsed Radiofrequency Combined With Liposomal Bupivacaine Subcutaneous Block for Herpes Zoster-Associated Neuralgia

NCT06959147

Herpes Zoster Pain Neuralgia, Postherpetic

RECRUITING PHASE4

Multimodal Nerve Block and Pulse Radiofrequency for Acute Herpes Zoster Pain

NCT06798662

Herpes Zoster (HZ)

NOT_YET_RECRUITING NA

Study of NGX-4010 for the Treatment of Postherpetic Neuralgia

NCT00300222

Peripheral Nervous System Diseases Pain Neuralgia +2 more

COMPLETED PHASE3

Esketamine Combined With PRF of DRG for Acute/Subacute Zoster-associated Pain

NCT06914206

Herpes Zoster

NOT_YET_RECRUITING NA

Study of NGX-4010 for the Treatment of Postherpetic Neuralgia

NCT00115310

Peripheral Nervous System Diseases Pain Neuralgia +2 more

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Herpes Zoster (HZ)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HL-PRF +DNS

On the basis of conventional drug treatment, dexmedetomidine nasal spray was administered before HL-PRF treatment, before bedtime on the day of the operation, and before bedtime on the 1st to 3rd days after the operation.

Group Type EXPERIMENTAL

dexmedetomidine nasal spray group

Intervention Type DRUG

Experimental group: Long duration high voltage pulse RF therapy plus dexmedetomidine nasal spray group

long duration high voltage pulse RF therapy group

Intervention Type OTHER

Experimental group: long duration high voltage pulse RF therapy group

HL-PRF

on the basis of conventional drug treatment, and the long-duration high-voltage pulse radiofrequency therapy was performed.

Group Type OTHER

long duration high voltage pulse RF therapy group

Intervention Type OTHER

Experimental group: long duration high voltage pulse RF therapy group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

dexmedetomidine nasal spray group

Experimental group: Long duration high voltage pulse RF therapy plus dexmedetomidine nasal spray group

Intervention Type DRUG

long duration high voltage pulse RF therapy group

Experimental group: long duration high voltage pulse RF therapy group

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with adverse reactions that are not effective in conventional drug treatment and cannot tolerate drugs
* The pain is located in the corresponding innervated are
* The pain affects the patient's daily life or work
* Diagnostic nerve block is effective and pain limited
* Recurrent herpes zoster pain
* Patients with shingle-related pain aged 40-85 years

Exclusion Criteria

* Infection at the puncture site, systemic infection that may spread, and malignant tumors near the puncture
* There are contraindications in minimally invasive interventional therapy such as coagulation function and platelet dysfunction
* Allergies to local anesthetics and inhalants
* Heart, lung, liver, kidney and other important organ failure, can not tolerate surgery
* Severe endocrine system diseases or long-term use of hormone or immunosuppressive therapy
* Patients with cardiac pacemakers, pregnant or lactating women
* Patients with cognitive dysfunction or poor coordination
* Patients who have been treated with electrical stimulation or PRF

Minimum Eligible Age

40 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No